Digestive System Diseases

633 trials 301 recruiting

Filter these 633 trials by phase, country and sponsor.

Open in Search →

Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING… Recruiting

2023-506626-37-00 Crohn's disease 4 2025-04-18
Effect of Carvedilol on the portosystemic gradient as measured by endoscopic ultrasound Recruiting

2024-518302-41-00 cirrhotic portal hypertension 4 2025-04-16
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial Recruiting

2023-506512-40-00 Acute Kidney Injury 5 2025-04-16
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Crohn's disease 4 2025-04-07
EXPOSURE Study Recruiting

2024-513353-73-00 Porto-Sinusoidal Vascular Disorder 4 2025-04-04
Early Phase II Exploratory, Open-Label, Non-Randomized Study of Neoadjuvant Dostarlimab Monotherapy in Participants with Untreated T3-4N0-2 … Recruiting

2024-512499-36-00 pMMR/MSS resectable Colon Cancer 4 2025-04-03
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
MAINTAIN-POP: EXL01 and prevention of post-operative recurrence of Crohn's disease Recruiting

2024-511357-22-00 Crohn's disease 4 2025-03-31
Efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with primary biliary cholangitis and n… Recruiting

2023-504086-23-00 Subjects with PBC with a non-optimal response to UDCA. 5 2025-03-27
Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-U… Recruiting

2023-506452-25-00 Ulcerative colitis 4 2025-03-27
HALT : Influence of Human Albumin supplementation on kidney dysfunction after Liver Transplantation Recruiting

2024-514804-14-00 Liver transplantation 6 2025-03-26
68-Ga-FAPI-46 positron emission tomography (PET) to better visualise pancreatic and bile duct cancer. Recruiting

2024-516486-36-00 cholangiocarcinoma (bile duct cancer) 10 2025-03-24
FARE Trial Recruiting

2023-506594-35-00 Rectal cancer 6 2025-03-24
A safety and efficacy study of RTX001 autologous macrophage therapy in participants with decompensated liver cirrhosis Recruiting

2024-516288-10-00 Liver Cirrhosis 9 2025-03-21
TECA study Recruiting

2024-513351-33-00 compensated advanced chronic liver disease 4 2025-03-21
Mechanisms of action on rectal motility of intrarectal botulinum toxin injections in patients with fecal incontinence - MECA-TOX Recruiting

2024-515256-21-00 Fecal incontinence 5 2025-03-21
Dose escalation of allogeneic Adipose derived Stroma/stem Cells for the treatment of Crohn’s fistula Recruiting

2024-511821-75-00 Crohn’s fistula 7 2025-03-13
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel … Recruiting

2024-511994-31-00 Short Bowel Syndrome and Intestinal Failure (SBS-IF) wi 4 2025-03-10
Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastat… Recruiting

2023-507873-16-00 1st line treatment for unresectable metastatic colorect 11 2025-03-04
Portal hypertension in cirrhosis Recruiting

2023-508535-32-00 Portal hypertension (PHT) and consequences in complicat 4 2025-03-04
A Study to Test the Activity and Safety of Vixarelimab in Patients with Moderate to Severe Active Ulcerative Colitis Recruiting

2024-516287-29-00 Moderate to Severe Active Ulcerative Colitis (UC) 3 2025-02-26
A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting… Recruiting

2024-514685-39-00 Irritable Bowel Syndrome (IBS) type D 4 2025-02-25
A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting

2024-513533-20-00 Crohn’s Disease or Ulcerative Colitis 5 2025-02-25